Fig. 2.

Effect of DC-IL-12 therapy on antitumor immune responses. a Antitumor effect of IL-12 treatment on MethA model. The treatment protocol was the same as in RENCA model. Each group included 7–8 mice. The differences between DC-IL-12 + AL and all control groups were statistically significant (P < 0.05). b Spleens from mice of indicated treatment groups were individually harvested and assayed for IFN-γ secretion, using an ELISPOT assay. Each group included 4 mice. Mean ± SD are shown. The differences between control groups and DC-IL-12 + AL groups were significant (P < 0.05). c Detection of CD4⁺ and CD8⁺ T cells in tumor tissues of treated mice. Representative images and statistical analysis of the results are shown. d The proportion of Gr-1⁺CD11b⁺ MDSC in spleens of tumor-bearing mice, before and after therapy with DC-IL-12 in combination with DC-IFN-α and AL. Mean ± SD of three mice per group. e Cytotoxic activity of DCs transduced with IL-12 and activated with ligand. Experiments were performed in duplicates in standard 4 h ⁵¹Cr-release assay